Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2516
Source ID: NCT00715780
Associated Drug: Soluble Human Insulin
Title: Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: soluble human insulin|DRUG: biphasic human insulin|DRUG: insulin NPH|DRUG: insulin aspart|DRUG: biphasic insulin aspart|DRUG: insulin detemir
Outcome Measures: Primary: Incidence of major hypoglycaemic episodes, during 26 weeks of insulin therapy | Secondary: Frequency and type of hypoglycaemic episodes, during 26 weeks of insulin therapy|Frequency and type of adverse events, during 26 weeks of insulin therapy|Frequency and type of adverse drug reactions, during 26 weeks of insulin therapy|Change in HbA1c from baseline, during 26 weeks of insulin therapy|Change in PPG from baseline, during 26 weeks of insulin therapy|Change in FPG from baseline, during 26 weeks of insulin therapy|Subjects' insulin treatment satisfaction, during 26 weeks of insulin therapy|Physicians' satisfaction with insulin therapy, during 26 weeks of insulin therapy|Weight change, at the end of the study|Percentage of patients reaching the target of HbA1c less than 7.5%, at the end of the study|Percentage of patients reaching the target of HbA1c less than 7%, at the end of the study|Percentage of patients reaching the target of HbA1c less than 6.5%, at the end of the study
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 1667
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2008-06
Completion Date: 2009-07
Results First Posted:
Last Update Posted: 2016-11-06
Locations: Novo Nordisk Investigational Site, Jakarta, 12520, Indonesia
URL: https://clinicaltrials.gov/show/NCT00715780